ERASCA INC (ERAS)
US29479A1088 - Common Stock
Commit To Purchase Erasca At $1, Earn 10.3% Annualized Using Options
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
ERAS stock results show that Erasca beat analyst estimates for earnings per share the fourth quarter of 2023.
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Erasca (NASDAQ:ERAS) just reported results for the fourth quarter of 2023.Erasc...
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026...
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts...
Commit To Purchase Erasca At $1.50, Earn 17.4% Annualized Using Options
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
Consider the pros and cons of buying these penny stocks, which can deliver risk-adjusted returns to investors' portfolios.
Bargain Hunters Take Note: Insider Cluster-Buying At ERAS
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more...
Erasca CEO Lim buys stock worth $1.7M - filing (NASDAQ:ERAS)
Erasca (NASDAQ:ERAS) CEO Jonathan Lim disclosed in an SEC filing on Wednesday after the bell a purchase of 1 million shares of the company worth $1.7...
Erasca director Alexander Casdin discloses purchase of 30K shares (NASDAQ:ERAS)
Erasca director purchases 30,000 shares worth $49,785, driving up ERAS stock by 7.8%.
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma;...
Erasca GAAP EPS of -$0.20 beats by $0.01 (NASDAQ:ERAS)
Erasca (ERAS) beats expectations with Q3 GAAP EPS of -$0.20.
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs ...
Erasca to Present at Upcoming Investor Conferences in November
Erasca to Present at Upcoming Investor Conferences in November
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Why Shares of Erasca Are Jumping Tuesday
The company's chairman and CEO bought more than $2.025 million worth of company stock.
Erasca Chairman & CEO disposes stake worth $2.03M (NASDAQ:ERAS)
Erasca CEO Jonathan E Lim sells 1M company shares for $2.03M, leaving him with around 19.46M shares.
Erasca to Present at the Cantor Global Healthcare Conference
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Commit To Buy Erasca At $2.50, Earn 28.3% Annualized Using Options
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b...